EPITRAN

ABSTRACT

The proposed COST actions aims at fostering the development of the emerging field of epitranscriptomics in Europe. We believe that, by understanding the role of RNA modifications in physiology and pathology, novel and powerful disease biomarkers and drug targets could be identified. This will in turn lead to the development of a whole new class of diagnostic tools and targeted therapies, with particular attention devoted to cancer treatment. Furthermore, mechanistic understanding of this set of phenomena will allow to deepen our understanding of the contribution of post-transcriptional regulation of gene expression to proteome and thus phenotype variation.

By implementing collaborative efforts, data sharing and mobility-based learning opportunities, this COST action will accelerate discovery in the epitranscriptomics field and contribute to the ultimate realization of this vision. Tightly integrating biotech companies in this networking initiatives will be key to the complete achievement of the action goals and a considerable added value for the European biomedical sector, potentially offering a competitive advantage in the ensuing market.